B- Cell Lymphomas - Pipeline Review, H2 2012

B- Cell Lymphomas - Pipeline Review, H2 2012

Sep 2012 Global Markets Direct Lymphoma333 Pages Price :
$ 2500

B-Cell Lymphomas Pipeline Review, H2 2012

Global Markets Directs, 'B-Cell Lymphomas Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Lymphomas. B-Cell Lymphomas Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for B-Cell Lymphomas.
  • A review of the B-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the B-Cell Lymphomas pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for B-Cell Lymphomas.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding B-Cell Lymphomas pipeline depth and focus of Indication therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
B-Cell Lymphomas Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for B-Cell Lymphomas 13
B-Cell Lymphomas Therapeutics under Development by Companies 15
B-Cell Lymphomas Therapeutics under Investigation by Universities/Institutes 22
Late Stage Products 34
Comparative Analysis 34
Mid Clinical Stage Products 35
Comparative Analysis 35
Early Clinical Stage Products 36
Comparative Analysis 36
Discovery and Pre-Clinical Stage Products 37
Comparative Analysis 37
B-Cell Lymphomas Therapeutics Products under Development by Companies 38
B-Cell Lymphomas Therapeutics Products under Investigation by Universities/Institutes 48
Companies Involved in B-Cell Lymphomas Therapeutics Development 75
Bristol-Myers Squibb Company 75
Johnson & Johnson 76
F. Hoffmann-La Roche Ltd. 77
Kyowa Hakko Kirin Co., Ltd. 78
Abbott Laboratories 79
Amgen Inc. 80
Sanofi-Aventis 81
AstraZeneca PLC 82
Eli Lilly and Company 83
GlaxoSmithKline plc 84
Seattle Genetics, Inc. 85
Genentech, Inc. 86
Antigenics, Inc. 87
MMR Information Systems, Inc. 88
MedImmune LLC 89
Gilead Sciences, Inc. 90
Merck & Co., Inc. 91
Emergent BioSolutions Inc. 92
Lentigen Corporation 93
Takeda Pharmaceutical Company Limited 94
Reliance Life Sciences Pvt. Ltd. 95
Piramal Healthcare Limited 96
Celltrion, Inc. 97
Millennium Pharmaceuticals, Inc. 98
Novartis AG 99
Astellas Pharma Inc. 100
Biocon Limited 101
BioMarin Pharmaceutical Inc. 102
Cephalon, Inc. 103
Glenmark Pharmaceuticals Ltd. 104
Pfizer Inc. 105
SuperGen, Inc. 106
Teva Pharmaceutical Industries Limited 107
Cell Therapeutics, Inc. 108
Genmab A/S 109
Alfacell Corporation 110
Celgene Corporation 111
Onyx Pharmaceuticals, Inc. 112
Bayer AG 113
Incyte Corporation 114
Merck KGaA 115
Celldex Therapeutics, Inc. 116
AEterna Zentaris Inc. 117
IMMUNOMEDICS, INC 118
MethylGene Inc 119
Curis, Inc. 120
Accentia Biopharmaceuticals, Inc. 121
Allos Therapeutics, Inc 122
Portola Pharmaceuticals, Inc. 123
Telik, Inc. 124
Pharmacyclics, Inc. 125
Senesco Technologies, Inc. 126
Green Cross Corporation 127
SymBio Pharmaceuticals Limited 128
Memgen, LLC. 129
Ascenta Therapeutics, Inc. 130
Provenance Biopharmaceuticals Corp. 131
Celentyx Ltd. 132
Fresenius Biotech GmbH 133
Semafore Pharmaceuticals, Inc. 134
Onconova Therapeutics, Inc 135
Immune System Therapeutics Ltd. 136
Intellikine, Inc. 137
Mirna Therapeutics, Inc. 138
Xencor, Inc. 139
Synthon Pharmaceuticals, Inc. 140
VentiRx Pharmaceuticals, Inc. 141
CureTech Ltd. 142
Cylene Pharmaceuticals, Inc. 143
Astellas Pharma GmbH 144
Dynamix Pharmaceuticals Ltd. 145
Cancer Therapeutics CRC Pty Ltd 146
Zenyaku Kogyo Co., Ltd. 147
LFB Biotechnologies, S.A.S.U. 148
Probiomed S.A. de C.V. 149
Shanghai CP Guojian Pharmaceutical Co.,Ltd. 150
PharmaTech International, Inc. 151
Cell>Point 152
Advancell 153
Fecal Incontinence Therapeutics Assessment 154
Assessment by Monotherapy Products 154
Assessment by Combination Products 155
Assessment by Route of Administration 156
Assessment by Molecule Type 158
Drug Profiles 160
obinutuzumab - Drug Profile 160
enzastaurin hydrochloride - Drug Profile 161
rituximab - Drug Profile 163
BiovaxID - Drug Profile 166
bortezomib - Drug Profile 168
bendamustine hydrochloride - Drug Profile 169
rituximab - Drug Profile 171
Rituximab + Fludarabine + Cyclophosphamide - Drug Profile 172
Bendamustine + Rituximab - Drug Profile 174
Cyclophosphamide + Epirubicin + Vincristine + Prednisone - Drug Profile 175
Rituximab + Chlorambucil - Drug Profile 177
Mitoxantrone + Chlorambucil + Dexamethasone - Drug Profile 178
Mitoxantrone + Dexamethasone + Fludarabine - Drug Profile 180
fludarabine phosphate - Drug Profile 181
Treanda + Rituxan - Drug Profile 182
lenalidomide - Drug Profile 184
Arzerra + Bendamustine - Drug Profile 186
Arzerra + DHAP + Stem Cell Transplant - Drug Profile 188
Pixantrone + Rituximab - Drug Profile 191
Avastin + R-CHOP - Drug Profile 192
RG7159 + CHOP - Drug Profile 194
Filgrastim + Rituximab + Carboplatin + Etoposide + Ifosfamide - Drug Profile 197
Fludarabine + Total Body Irradiation + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 199
EPOCH + Rituximab - Drug Profile 200
Asparaginase + Cyclophosphamide + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Mercaptopurine + Methotrexate + Methylprednisolone + Mitoxantrone Hydrochloride + Prednisone + Vincristine Sulfate + Radiation Therapy - Drug Profile 202
Rituximab + Cyclophosphamide + Vincristine + Prednisone + Doxorubicin - Drug Profile 205
Rituximab + Cyclophosphamide + Hydroxydaunorubicin Hydrochloride + Oncovin + Prednisone - Drug Profile 207
Rituximab + Cyclophosphamide + Hydroxydaunorubicin Hydrochloride + Oncovin + Prednisone + Darbepoetin Alpha - Drug Profile 209
VELCADE-R-CAP - Drug Profile 211
ofatumumab - Drug Profile 213
Cyclophosphamide + Vincristine + Prednisolone + Mabthera + Radiotherapy - Drug Profile 217
Rituximab + Cyclophosphamide + Fludarabine - Drug Profile 219
Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Cisplatin + Dexamethasone + Cytarabine + Melphalan + Radiation Therapy + Stem Cell Transplantation - Drug Profile 220
R-CHOP + Radiation Therapy - Drug Profile 222
Bexxar + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 224
Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine - Drug Profile 226
Cyclophosphamide + Doxorubicin + Prednisone + Vincristine + Iodine-131 Tositumomab - Drug Profile 228
FavId + Sargramostim + Rituximab - Drug Profile 230
Rituximab + Doxorubicin + Vincristine + Prednisone - Drug Profile 232
Rituximab + Fludarabine + Cyclophosphamide - Drug Profile 234
Carmustine + Cyclophosphamide + Cytarabine + Etoposide + Melphalan + Autologous Stem Cell Transplantation + Rituximab - Drug Profile 236
R-CHOP14 + Neulasta - Drug Profile 238
Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone - Drug Profile 240
ocaratuzumab - Drug Profile 242
DHAP + Rituximab - Drug Profile 243
ICE + RITUXIMAB - Drug Profile 244
Filgrastim + Rituximab + Sargramostim + CHOP Regimen + Carmustine + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Prednisone + Vincristine + Stem Cell Transplantation + Radiation Therapy - Drug Profile 245
Filgrastim + Rituximab + Sargramostim + CHOP Regimen + Carmustine + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Prednisone + Vincristine + Stem Cell Transplantation + Radiation Therapy - Drug Profile 248
Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Rituximab + G-CSF - Drug Profile 251
Cyclophosphamide + Vincristine + Prednisone + Epirubicin + Rituximab + G-CSF - Drug Profile 253
Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Rituximab + G-CSF - Drug Profile 256
R-FM - Drug Profile 259
R-CVP - Drug Profile 260
Cyclophosphamide + Prednisone + Epirubicin + Vinblastine + Rituximab + G-CSF - Drug Profile 262
R-CHOP14 + Darbepoetin Alfa - Drug Profile 264
rituximab - Drug Profile 266
Bleomycin Sulfate + Rituximab + CHOP Regimen + EPOCH Regimen + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Methotrexate + Mitoxantrone Hydrochloride + Prednisolone + Prednisone + Vincristine Sulfate - Drug Profile 267
Filgrastim + Recombinant Interferon Alfa + Carmustine + Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Melphalan + Radiation Therapy + Peripheral Blood Stem Cell Transplantation - Drug Profile 271
Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine + Filgrastim + Carboplatin + Etoposide + Ifosfamide - Drug Profile 274
R-CHOP - Drug Profile 277
Revlimid + Rituxan - Drug Profile 279
Bortezomib + Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisolone - Drug Profile 280
CMAB304 + CHOP - Drug Profile 282
Rituximab Biosimilar + CHOP - Drug Profile 284
B-Cell Lymphomas Therapeutics Drug Profile Updates 286
B-Cell Lymphomas Therapeutics Discontinued Products 304
B-Cell Lymphomas Therapeutics - Dormant Products 310

Appendix 328
Methodology 328
Coverage 328
Secondary Research 328
Primary Research 328
Expert Panel Validation 328
Contact Us 329
Disclaimer 329

List of Table


Number of Products Under Development for B-Cell Lymphomas, H2 2012 17
Products under Development for B-Cell Lymphomas Comparative Analysis, H2 2012 18
Number of Products under Development by Companies, H2 2012 20
Number of Products under Development by Companies, H2 2012 (Contd..1) 21
Number of Products under Development by Companies, H2 2012 (Contd..2) 22
Number of Products under Development by Companies, H2 2012 (Contd..3) 23
Number of Products under Development by Companies, H2 2012 (Contd..4) 24
Number of Products under Development by Companies, H2 2012 (Contd..5) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 30
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 37
Comparative Analysis by Late Stage Development, H2 2012 38
Comparative Analysis by Mid Clinical Stage Development, H2 2012 39
Comparative Analysis by Early Clinical Stage Development, H2 2012 40
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 41
Products under Development by Companies, H2 2012 42
Products under Development by Companies, H2 2012 (Contd..1) 43
Products under Development by Companies, H2 2012 (Contd..2) 44
Products under Development by Companies, H2 2012 (Contd..3) 45
Products under Development by Companies, H2 2012 (Contd..4) 46
Products under Development by Companies, H2 2012 (Contd..5) 47
Products under Development by Companies, H2 2012 (Contd..6) 48
Products under Development by Companies, H2 2012 (Contd..7) 49
Products under Development by Companies, H2 2012 (Contd..8) 50
Products under Development by Companies, H2 2012 (Contd..9) 51
Products under Investigation by Universities/Institutes, H2 2012 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 64
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 65
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 67
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 68
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 69
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 70
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 71
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 72
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 73
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 74
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 75
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 76
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 77
Products under Investigation by Universities/Institutes, H2 2012 (Contd..26) 78
Bristol-Myers Squibb Company, H2 2012 79
Johnson & Johnson, H2 2012 80
F. Hoffmann-La Roche Ltd., H2 2012 81
Kyowa Hakko Kirin Co., Ltd., H2 2012 82
Abbott Laboratories, H2 2012 83
Amgen Inc., H2 2012 84
Sanofi-Aventis, H2 2012 85
AstraZeneca PLC, H2 2012 86
Eli Lilly and Company, H2 2012 87
GlaxoSmithKline plc, H2 2012 88
Seattle Genetics, Inc., H2 2012 89
Genentech, Inc., H2 2012 90
Antigenics, Inc., H2 2012 91
MMR Information Systems, Inc., H2 2012 92
MedImmune LLC, H2 2012 93
Gilead Sciences, Inc., H2 2012 94
Merck & Co., Inc., H2 2012 95
Emergent BioSolutions Inc., H2 2012 96
Lentigen Corporation, H2 2012 97
Takeda Pharmaceutical Company Limited, H2 2012 98
Reliance Life Sciences Pvt. Ltd., H2 2012 99
Piramal Healthcare Limited, H2 2012 100
Celltrion, Inc., H2 2012 101
Millennium Pharmaceuticals, Inc., H2 2012 102
Novartis AG, H2 2012 103
Astellas Pharma Inc., H2 2012 104
Assessment by Monotherapy Products, H2 2012 158
Assessment by Combination Products, H2 2012 159
Assessment by Stage and Route of Administration, H2 2012 161
Assessment by Stage and Molecule Type, H2 2012 163
B-Cell Lymphomas Therapeutics Drug Profile Updates 290
B-Cell Lymphomas Therapeutics Discontinued Products 308
B-Cell Lymphomas Therapeutics Discontinued Products (Contd..1) 309
B-Cell Lymphomas Therapeutics Discontinued Products (Contd..2) 310
B-Cell Lymphomas Therapeutics Discontinued Products (Contd..3) 311
B-Cell Lymphomas Therapeutics Discontinued Products (Contd..4) 312
B-Cell Lymphomas Therapeutics Discontinued Products (Contd..5) 313
B-Cell Lymphomas Therapeutics Dormant Products 314
B-Cell Lymphomas Therapeutics Dormant Products (Contd..1) 315
B-Cell Lymphomas Therapeutics Dormant Products (Contd..2) 316
B-Cell Lymphomas Therapeutics Dormant Products (Contd..3) 317
B-Cell Lymphomas Therapeutics Dormant Products (Contd..4) 318
B-Cell Lymphomas Therapeutics Dormant Products (Contd..5) 319
B-Cell Lymphomas Therapeutics Dormant Products (Contd..6) 320
B-Cell Lymphomas Therapeutics Dormant Products (Contd..7) 321
B-Cell Lymphomas Therapeutics Dormant Products (Contd..8) 322
B-Cell Lymphomas Therapeutics Dormant Products (Contd..9) 323
B-Cell Lymphomas Therapeutics Dormant Products (Contd..10) 324
B-Cell Lymphomas Therapeutics Dormant Products (Contd..11) 325
B-Cell Lymphomas Therapeutics Dormant Products (Contd..12) 326
B-Cell Lymphomas Therapeutics Dormant Products (Contd..13) 327
B-Cell Lymphomas Therapeutics Dormant Products (Contd..14) 328
B-Cell Lymphomas Therapeutics Dormant Products (Contd..15) 329
B-Cell Lymphomas Therapeutics Dormant Products (Contd..16) 330
B-Cell Lymphomas Therapeutics Dormant Products (Contd..17) 331

List of Chart


Number of Products under Development for B-Cell Lymphomas, H2 2012 17
Products under Development for B-Cell Lymphomas Comparative Analysis, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 26
Late Stage Products, H2 2012 38
Mid Clinical Stage Products, H2 2012 39
Early Clinical Stage Products, H2 2012 40
Discovery and Pre-Clinical Stage Products, H2 2012 41
Assessment by Monotherapy Products, H2 2012 158
Assessment by Combination Products, H2 2012 159
Assessment by Route of Administration, H2 2012 160
Assessment by Stage and Route of Administration, H2 2012 161
Assessment by Molecule Type, H2 2012 162
Assessment by Stage and Molecule Type, H2 2012 163

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2500
$ 5000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top